SEARCH

SEARCH BY CITATION

References

  • 1
    Kittleson MD, Kienle RD. Pathophysiology of heart failure. In: Kittleson MD, Kienle RD, eds. Small Animal Cardiovascular Medicine, 1st ed. St Louis, MO: Mosby Inc; 1998:136148.
  • 2
    Abbott JA. Acquired valvular disease. In: Tilley LP, Smith FWK Jr, Oyama MA, Sleeper MM, eds. Manual of Canine and Feline Cardiology, 4th ed. Philadelphia, PA: WB Saunders; 2008:110138.
  • 3
    Ware WA BJ. Pulmonary edema. In: Fox PR, Sisson D, Moïse NS, eds. Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, 2nd ed. Philadelphia, PA: WB Saunders; 1999:251262.
  • 4
    Strickland KN. Pathophysiology and therapy of heart failure. In: Tilley LP, Smith FWK Jr, Oyama MA, Sleeper MM, eds. Manual of Canine and Feline Cardiology, 4th ed. Philadelphia, PA: WB Saunders; 2008:288314.
  • 5
    Carceles MD, Aleixandre F, Fuente T, et al. Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Eur J Anaesthesiol 2003;20:205211.
  • 6
    van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989;14(Suppl 2):S1S6.
  • 7
    Fuentes VL, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002;16:255261.
  • 8
    Smith PJ, French AT, Van Israel N, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005;46:121130.
  • 9
    Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249261.
  • 10
    O'Grady MR, Minors SL, O'Sullivan ML, et al. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med 2008;22:897904.
  • 11
    Haggstrom J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally-occurring myxomatous mitral valve disease: The QUEST study. J Vet Intern Med 2008;22:11241135.
  • 12
    Tissier R, Chetboul V, Moraillon R, et al. Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy. Cardiovasc Toxicol 2005;5:4351.
  • 13
    Chetboul V, Lefebvre HP, Sampedrano CC, et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: A prospective, controlled, blinded, and randomized study. J Vet Intern Med 2007;21:742753.
  • 14
    Ishikawa T, Tanaka R, Suzuki S, et al. Daily rhythms of left atrial pressure in Beagle dogs with mitral valve regurgitation. J Vet Intern Med 2009;23:824831.
  • 15
    Ishikawa T, Tanaka R, Suzuki S, et al. The effect of angiotensin-converting enzyme inhibitors of left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med 2010;24:342347.
  • 16
    Suzuki S, Ishikawa T, Hamabe L, et al. The effect of furosemide on left atrial pressure in dogs with mitral valve regurgitation. J Vet Intern Med 2011;25:244250.
  • 17
    Yasuma F, Hayano JI. Impact of acute hypoxia on heart rate and blood pressure variability in conscious dogs. Am J Physiol Heart Circ Physiol 2000;279:H23442349.
  • 18
    Thrasher TN. Effects of chronic baroreceptor unloading on blood pressure in the dog. Am J Physiol Regul Integr Comp Physiol 2005;288:R863871.
  • 19
    Rishniw M, Erb HN. Evaluation of four 2-dimensional echocardiographic methods of assessing left atrial size in dogs. J Vet Intern Med 2000;14:429435.
  • 20
    Muzzi RA, de Araujo RB, Muzzi LA, et al. Regurgitant jet area by Doppler color flow mapping: Quantitative assessment of mitral regurgitation severity in dogs. J Vet Cardiol 2003;5:3338.
  • 21
    Kittleson MD, Kienle RD. Pulmonary arterial and systemic arterial hypertension. In: Kittleson MD, Kienle RD, eds. Small Animal Cardiovascular Medicine, 1st ed. St Louis, MO: Mosby Inc; 1998:523542.
  • 22
    Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: A prospective randomized trial. J Cardiothorac Vasc Anesth 2008;22:406413.
  • 23
    Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23:11421150.
  • 24
    The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: The effects of pimobendan on chronic heart failure study. Circ J 2002;66:149157.
  • 25
    Walter M, Liebens I, Goethals H, et al. Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. Br J Clin Pharmacol 1988;25:323329.
  • 26
    Renard M, Walter M, Liebens I, et al. Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. Chest 1988;93:11591164.
  • 27
    Ohte N, Cheng CP, Suzuki M, et al. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1997;282:2331.
  • 28
    Kanno N, Kuse H, Kawasaki M, et al. Effects of pimobendan for mitral valve regurgitation in dogs. J Vet Med Sci 2007;69:373377.
  • 29
    Ouellet M, Belanger MC, Difruscia R, et al. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. J Vet Intern Med 2009;23:258263.
  • 30
    Atkinson KJ, Fine DM, Thombs LA, et al. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 2009;23:11901196.
  • 31
    Teshima K, Asano K, Sasaki Y, et al. Assessment of left ventricular function using pulsed tissue Doppler imaging in healthy dogs and dogs with spontaneous mitral regurgitation. J Vet Med Sci 2005;67:12071215.
  • 32
    Oyama MA, Sisson DD, Bulmer BJ, et al. Echocardiographic estimation of mean left atrial pressure in a canine model of acute mitral valve insufficiency. J Vet Intern Med 2004;18:667672.
  • 33
    Schober KE, Bonagura JD, Scansen BA, et al. Estimation of left ventricular filling pressure by use of Doppler echocardiography in healthy anesthetized dogs subjected to acute volume loading. Am J Vet Res 2008;69:10341049.
  • 34
    Schober KE, Hart TM, Stern JA, et al. Detection of congestive heart failure in dogs by Doppler echocardiography. J Vet Intern Med 2010;24:13581368.